Mesoblast Ltd’s Strong Performance Drives Share Price Growth
Mesoblast Ltd (ASX: MSB) has seen its share price gain attention following the company’s recent announcement of Ryoncil® net sales reaching US$30.3 million for the quarter ending March 2026. This marks a significant milestone, as total net revenue since the product’s launch now approaches US$100 million.
Key Highlights from Mesoblast’s Report
- Ryoncil® Sales: The third quarter to March 2026 saw net sales of Ryoncil® reach US$30.3 million.
- Revenue Milestone: Since its launch, Ryoncil® has generated nearly US$100 million in net revenue.
- Sales Growth: Strong sales performance in February and March helped offset a seasonal dip in January.
- FDA Approval: Ryoncil® is the only FDA-approved cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
What Investors Need to Know
Mesoblast’s first year of Ryoncil® sales has significantly strengthened its balance sheet. This financial boost is being used to fund label extensions and late-stage clinical programs. The company has also reaffirmed its leadership position by being the first to market with an FDA-approved mesenchymal stromal cell therapy.
In addition, Mesoblast will host its first R&D Day in New York on 8 April 2026. During this event, the company will outline growth strategies for Ryoncil® and provide updates on its late-stage product pipeline. Investors can participate in the live webcast or access a replay on the company’s website.
Future Plans for Mesoblast
The company is currently focused on expanding the approved uses of Ryoncil®. This includes conducting studies in adults with SR-aGvHD and in patients with biologic-resistant inflammatory bowel disease. Mesoblast is also advancing the clinical development of rexlemestrocel-L for heart failure and chronic low back pain.
Ongoing investment in its product pipeline and global partnerships is expected to keep Mesoblast at the forefront of cell therapy for major inflammatory diseases.
Mesoblast Share Price Performance
Over the past 12 months, Mesoblast shares have increased by 29%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen by 20% over the same period.
Considerations for Potential Investors
Before investing in Mesoblast Limited shares, it is important to consider various factors. Motley Fool investing expert Scott Phillips recently highlighted what he believes are the five best stocks for investors to buy right now, and Mesoblast Limited was not among them.
The online investing service he has run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have delivered substantial returns. Currently, Scott believes there are five stocks that may be better buys.
Additional Reading
- Capricorn Metals delivers solid Q3 FY26 gold production and growth update
- Summerset Group Q1 2026 sales rise on robust demand
- Ramelius Resources confirms guidance, strong March quarter gold output
- Bank of Queensland announces $3.7bn loan sale and capital partnership with Challenger
- Guzman y Gomez posts 20% Q3 FY26 sales growth
Disclaimer
The Motley Fool Australia contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.
